Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lifecare AS ( (DE:LFC0) ) has provided an update.
Lifecare ASA announced that its ongoing veterinary longevity study, LFC-SEN-002, has confirmed positive findings from its second subject, reinforcing the safety and biocompatibility of its CGM device for long-term use. The study, which builds on previous human data, aims to validate glucose measurement performance and expand its scope to include both healthy and diabetic animals. In response to misleading media coverage affecting its market valuation, Lifecare plans to file a formal complaint with the Norwegian Press Complaints Commission to protect shareholder trust and uphold transparent market communication.
More about Lifecare AS
Lifecare ASA is a MedTech company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company specializes in medical sensor technology that monitors various body analytes, utilizing osmotic pressure as a sensing principle. Their technology is applicable for both human and veterinary use.
Average Trading Volume: 322,771
Current Market Cap: NOK171.5M
See more insights into LFC0 stock on TipRanks’ Stock Analysis page.